programmed cell death protein 1 gene-deficient activated T cells

Programmed cell death protein 1 gene-deficient activated T cells is an autologous cell therapy developed by Anhui Kedun Biotechnology for the treatment of hepatocellular carcinoma. The therapy involves harvesting a patient's own T cells and using CRISPR/Cas9 gene-editing technology to knock out the PDCD1 gene, which encodes the PD-1 checkpoint protein. By eliminating PD-1 expression, these gene-deficient T cells are rendered resistant to the inhibitory signals typically transmitted by PD-L1 and PD-L2 ligands within the tumor microenvironment. This modification aims to prevent T-cell exhaustion and enhance the sustained anti-tumor activity of the re-infused cells against advanced liver cancer. The product is currently being evaluated in Phase 1 clinical trials to assess safety and efficacy in patients with advanced HCC.

Other names

PD-1 knockout T cellsPD1 knockout T cellsPD 1 knockout T cellsPD-1-KO T cellsPD1-KO T cellsPD 1-KO T cellsPD-1 gene-deficient T cellsPD1 gene-deficient T cellsPD 1 gene-deficient T cells